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Abstract
Very long-term bowel function after total mesorectal excision (TME) with or without preoperative short-course
radiotherapy (PRT) for rectal cancer was examined. After > 14 years, almost one half of 242 nonstoma patients
reported severe bowel dysfunction (major low anterior resection syndrome [LARS]), which was associated with
poorer health-related quality of life. PRT and age £ 75 years at the follow-up point increased the risk of major
LARS in addition to TME. Patients should be adequately informed of such long-lasting adverse effects.
Background: We investigated very long-term bowel function after total mesorectal excision (TME) with or without
preoperative short-course radiotherapy (PRT) for rectal cancer, the risk factors for bowel dysfunction, and the
association of bowel dysfunction with health-related quality of life (HRQL). Patients and Methods: In the TME trial
(1996-1999), 1530Dutch patientswith rectal cancerwere randomized to TMEpreceded by 5 5GyPRT or TME alone. A
set of questionnaires was sent to the surviving patients (n¼ 583) in 2012. The questionnaires included the Low Anterior
Resection Syndrome Score (LARS score), European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire Core (EORTCQLQ-C30) and Colorectal Module (EORTCQLQ-CR29). The LARS score range was divided
into “no LARS,” “minor LARS,” and “major LARS” categories in ascending severity of bowel dysfunction. The potential
risk factors for major LARS were tested on multivariable analysis. The HRQL was compared between the LARS score
categories.Results: Of the 478 respondents, 242 nonstoma patients were included in the present analysis. Themedian
interval since treatment was 14.6 years, and the median age at the follow-up point was 75 years. Major LARS was re-
ported by 46%of all patients (56%PRT plus TME vs. 35%TME). PRT (odds ratio [OR], 3.0; 99% conﬁdence interval [CI],
1.3-6.9) and age  75 years at the follow-up point (OR, 2.4; 99% CI, 1.1-5.5) increased the risk of major LARS. Gender,
tumor height, anastomotic leakage, type of anastomosis, interval since treatment, and comorbid diabetes were
not signiﬁcant. Patients with major LARS fared worse in many HRQL domains (P < .01; score difference > 5% of score
range). Conclusion: A considerable proportion of nonstoma patients endured major LARS years after TME. PRT and
age  75 years at follow-up pose further risks of major LARS in addition to surgery. Major LARS is associated with
reduced HRQL.
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Introduction
The introduction of total mesorectal excision (TME) was a major
breakthrough in the treatment of rectal cancer, leading to sub-
stantially improved local control and survival.1,2 The additional
beneﬁt of preoperative short-course radiotherapy (PRT) has been
conﬁrmed in the TME and Medical Research Council CR07 trials:
PRT greatly reduces local recurrence when used in addition to
TME, but does not change overall survival.3-6
However, both TME and PRT result in side effects, of which
bowel dysfunction is the most common and serious, especially given
the emphasis on sphincter preservation in rectal cancer treatment.
Although numerous studies have explored the impact of rectal
cancer surgery and radiotherapy (RT) on bowel function,7,8 they
have often been limited by the instrument used to measure bowel
function. Many of the studies used nonvalidated questionnaires,7,8
including the 5-year follow-up of the TME trial, in which irradi-
ated patients reported poorer bowel function.9 Even when validated
questionnaires were used, most were fecal incontinence in-
struments,7 which only assess the continence aspect of bowel
function. However, bowel dysfunction after rectal resection (with or
without RT), referred to as anterior resection syndrome or low
anterior resection syndrome (LARS), can manifest itself in various
symptoms other than incontinence, including frequent bowel
movements, urgency, and clustering.10Figure 1 Flow Chart of Study Patients
Abbreviations: LARS ¼ low anterior resection syndrome; TME ¼ total mesorectal excision.A small number of studies have not been bound by these limi-
tations, using validated instruments to examine LARS more
comprehensively, beyond fecal incontinence.11-15 The Low Anterior
Resection Syndrome Score (LARS score) is 1 such instrument.16 It
is a concise questionnaire designed for quick evaluation of a diverse
range of LARS symptoms that patients ﬁnd the most bothersome,
and is suitable for routine use in clinical settings.16 These studies
found that LARS is prevalent, and identiﬁed several risk factors for
severe LARS in addition to surgery, the strongest of which was
PRT.11,12,15 Nevertheless, these studies were observational, and
their ﬁndings need to be veriﬁed in a randomized controlled trial.
Moreover, the longest median follow-up period of these studies
was around 5 years; however, a large proportion of the increasing
number of rectal cancer survivors have been living > 1 decade after
treatment. The TME trial has shown that the 10-year overall sur-
vival was 48% for the PRT plus TME group and 49% for the TME
alone group.5 Little is known about the impact of rectal cancer
treatment on bowel function after such an extended period.
Because of these evidence gaps, we performed the present follow-
up study of the TME trial cohort > 14 years after treatment. The
primary aims were to rigorously investigate patients’ very long-term
bowel function using the LARS score, and to determine the risk
factors for severe LARS. The secondary aim was to examine the as-
sociation of severe LARS with health-related quality of life (HRQL).Clinical Colorectal Cancer June 2015 - 107
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Data Collection
The TME trial has been previously described in detail.3-5 In brief,
from January 1996 to December 1999, 1861 patients (1530 from
The Netherlands) with clinically resectable rectal adenocarcinoma
without evidence of distant metastasis at the time of enrollment were
randomized to either 5  5 Gy PRT (delivered using a 3- or 4-ﬁeld
technique over 5-7 days) followed by TME within 1 week, or TME
alone. The inferior margin of the tumor had to be located below the
level of S1/S2 and not farther than 15cm from the anal verge.
Because of logistic feasibility, only Dutch patients were followed
up in the present study (Figure 1). In July to August 2012, at which
time the median follow-up duration was 14.4 years, a set of ques-
tionnaires was sent by mail to the surviving patients who had pre-
viously consented to further questionnaire follow-up. Information
on vital status was provided by the Central Bureau for Genealogy
and patients’ general practitioners. Those who did not respond
initially were sent a second questionnaire set in September 2012.Figure 2 The Low Anterior Resection Syndrome Score (LARS score)
Clinical Colorectal Cancer June 2015Only patients without a stoma were eligible for the present study
(Figure 1). Stoma status was ascertained in the questionnaire set.
Measures
The questionnaire set contained the following instruments.
LARS Score. The LARS score was developed from and validated
on a large, nationwide cohort of 961 Danish patients.16 It has
subsequently been translated into other languages, including
Swedish, Spanish, German, English, and Dutch. Through the
standardized validation of the former 3 translated versions
(Swedish, Spanish, and German), it was found that the LARS
score performs equally well in several different European coun-
tries, and that as long as the proper translation procedure is fol-
lowed, validation of a newly translated version would only be
necessary if the score is intended for use in cultures dissimilar to
the European culture.17 Despite this, the latter 2 translated ver-
sions (English and Dutch) are being validated to fully conﬁrm











Male 64 (54.2) 69 (55.6)
Female 54 (45.8) 55 (44.4)
TNM stage .29
0 1 (0.9) 6 (4.9)
I 48 (40.6) 48 (38.7)
II 30 (25.4) 35 (28.2)
III 38 (32.2) 35 (28.2)
IV 1 (0.9) 0
Tumor distance from anal
vergea (cm)
.02
<5 3 (2.5) 14 (11.4)
5-9.9 58 (49.2) 60 (48.8)
10 57 (48.3) 49 (39.8)
Interval since treatment (years) .21
Median 14.4 14.7
Range 12.6-16.6 12.6-16.5
Data presented as n (%), unless otherwise noted.
Abbreviations: PRT ¼ preoperative short-course radiotherapy; TME ¼ total mesorectal excision.
aFor 1 TME only patient, the tumor distance from the anal verge could not be determined.
Tina Yen-Ting Chen et althe validity and reliability of the LARS score for these populations
(validation of the English version has just been completed and will
be published shortly; validation of the Dutch version is in prog-
ress). The items and scoring algorithm of the LARS score are
shown in Figure 2. All items must be completed for a valid score
to be generated. Only patients with a valid LARS score were
included in the present analysis (Figure 1).
European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire Core and Colorectal Module. The Eu-
ropean Organization for Research and Treatment of Cancer Quality
of Life Questionnaire Core (EORTC QLQ-C30) and Colorectal
Module (EORTC QLQ-CR29) are well-established HRQL
instruments.18,19 All 15 scales of the EORTC QLQ-C30 and 22 of
the 28 EORTC QLQ-CR29 scales (stoma-related scales were
excluded) were analyzed.
Statistical Analysis
The proportion of patients in each LARS score severity category
was compared between the treatment arms (PRTþTME vs. TME)
using the c2 test. Also, the proportion of patients choosing each
response option in the individual LARS score items was similarly
compared. Using clinical judgment and research to date, the po-
tential risk factors for severe LARS (major LARS vs. minor or no
LARS) were tested using multiple logistic regression analysis: PRT
(yes vs. no), age ( median vs. > median age), gender (female vs.
male), distance of the tumor from the anal verge (< 5, 5-9.9, and 
10 cm), anastomotic leakage (yes vs. no), type of anastomosis
(endeside, endeend, and pouch), interval since treatment (years),
and the presence of comorbid diabetes (yes vs. no).
The EORTC HRQL instruments were scored according to
guidelines. These scores were compared between the LARS score
categories (major LARS vs. minor or no LARS) using the Mann-
Whitney U test.
Statistical signiﬁcance was set at P < .01 to correct for multiple
testing. In line with current evidence, a HRQL score difference
of > 5% of the total score range was considered clinically sig-
niﬁcant.20,21 A difference in HRQL had to be both statistically
and clinically signiﬁcant to be deemed signiﬁcant. The analyses




A total of 242 patients were included in the present analysis
(Figure 1). The median interval since treatment was 14.6 years
(range, 12.6-16.6 years), and the median age at the follow-up point
was 75 years (range, 39-95 years). The patients were equally
distributed between the 2 treatment arms (Table 1).
LARS Score
Overall, major LARS was experienced by 110 of the 242 patients
(46%), while 54 (22%) had minor LARS, and 78 (32%) reported
no LARS. A greater proportion of irradiated patients experienced
major LARS (56% vs. 35%; Figure 3A). Irradiated patients also
fared worse on all individual LARS score items, apart from incon-
tinence for ﬂatus (Figure 3B).Risk Factors for Major LARS
Of all the factors tested on multivariable analysis, PRT (odds
ratio [OR], 3.0; 99% conﬁdence interval [CI], 1.3-6.9) and age
 75 years at the follow-up point (OR, 2.4; 99% CI, 1.1-5.5)
were found to increase the likelihood of major LARS (Table 2).
HRQL and LARS Score
Patients with major LARS had worse scores than those of patients
with minor or no LARS in many of the HRQL domains measured
using the EORTC QLQ-C30 and EORTC QLQ-CR29 (Table 3).
Discussion
Numerous studies have already explored the impact of rectal cancer
surgery andRT on bowel function, with 2 systematic review andmeta-
analysis reports concluding that TME and PRT negatively affect long-
term bowel function.7,8 The report by Scheer et al7 derived a 35%
pooled incidence of fecal incontinence after curative anterior resection,
and pinpointed that PRT was associated with higher rates of post-
resection incontinence (P ¼ .006). The report by Loos et al8 found a
higher rate of stool incontinence after preoperative radio(chemo)
therapy and TME than TME alone (risk ratio, 1.67; 95% CI, 1.36-
2.05). Nevertheless, the various studies included in these 2 systematic
review and meta-analysis reports adopted different deﬁnitions and
severity measures of bowel dysfunction.More importantly, the quality
of the vastmajority of the studies was limited by the instrument used to
examine bowel function. Many of the studies used nonvalidated
questionnaires; also, among the studies that did use validatedClinical Colorectal Cancer June 2015 - 109
Figure 3 (A) Comparison of Patient Distribution Across LARS Score Severity Categories Between Treatment Arms (B) Comparison of
Patient Distribution Across Response Options of Individual LARS Score Items Between Treatment Arms
Abbreviations: LARS ¼ low anterior resection syndrome; PRT ¼ preoperative short-course radiotherapy; TME ¼ total mesorectal excision.
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Table 2 Potential Risk Factors for Major LARS
Risk Factor Patients (n) OR (99% CI)
PRT
Yesa 118 3.0 (1.3-6.9)
No 124 Reference
Age at follow-up (years)
75a 127 2.4 (1.1-5.5)
>75 115 Reference
Gender
Female 109 1.7 (0.8-3.7)
Male 133 Reference
Tumor distance from anal vergeb (cm)
<5 17 3.6 (0.7-18.2)
5-9.9 118 1.4 (0.6-3.1)
10 106 Reference
Anastomotic leakage
Yes 16 1.6 (0.3-8.3)
No 226 Reference
Type of anastomosisc
End to side 145 2.5 (1.0-6.6)
End to end 26 2.7 (0.6-11.2)
Pouch 68 Reference
Interval since treatment (years) 242 1.0 (0.7-1.5)
Comorbid diabetesd
Yes 34 1.8 (0.6-5.6)
No 197 Reference
Abbreviations: CI ¼ conﬁdence interval; LARS ¼ low anterior resection syndrome; OR ¼ odds
ratio; PRT ¼ preoperative short-course radiotherapy.
aSigniﬁcant risk factor.
bTumor distance from anal verge could not be determined for 1 patient.
cType of anastomosis could not be determined for 3 patients.
dComorbid diabetes could not be determined for 11 patients.
Tina Yen-Ting Chen et alquestionnaires, most used a fecal incontinence instrument, such as the
Wexner score or Kirwan score.7,8 However, LARS is a disorder with
heterogeneous symptoms involving more than just incontinence, and
even validated fecal incontinence instruments cannot fully capture the
complexity of the problem.16 It has been revealed that urgency and
clustering are the most bothersome LARS symptoms for patients;
however, clinicians have tended to underestimate their impact, placing
more emphasis on incontinence and frequent bowel movements
instead.22 Therefore, any assessment of LARS that uses either a non-
validated questionnaire or a validated one that only focuses on
incontinence cannot be considered a truly sound assessment.
Our study is among the few that used validated instruments to
comprehensively examine the spectrum of LARS symptoms after
rectal cancer treatment.11-15 However, the other studies were
observational, with a longest median follow-up period of around
5 years. Our study stands out for the robust TME trial design and
the exceptionally long follow-up period. The TME trial was not
only randomized and controlled, but also included treatment
standardization and quality control measures.3 The long follow-up
duration enabled insight into the long-lasting impairment of
bowel function > 1 decade after treatment. Furthermore, our study
adopted a more stringent signiﬁcance level (P < .01).Although our study provided a stronger level of evidence than did
the earlier studies, our results should be interpreted in light of other
evidence. Two studies have previously used the LARS score to
evaluate bowel function after rectal cancer treatment.11,12 The study
by Emmertsen et al11 revealed that 46% of patients reported major
LARS at 12 months, with neoadjuvant therapy and TME (vs.
partial mesorectal excision) being the risk factors. In the population-
based study by Bregendahl et al,12 41% of patients experienced
major LARS after a median follow-up of 54 months. Neoadjuvant
therapy, TME, anastomotic leakage, age  64 years at surgery, and
female gender were identiﬁed as risk factors.12 Our ﬁndings were
mostly in keeping with the ﬁndings from these studies. In terms of
discrepancies, our female gender OR closely resembled that reported
by Bregendahl et al12 (1.7 vs. 1.35, respectively) and the narrow CIs
overlapped (99% CI, 0.8-3.7 vs. 95% CI, 1.02-1.79, respectively),
suggesting that our nonsigniﬁcant female gender result might not be
deﬁnitive. Bregendahl et al12 concluded that anastomotic leakage
should be considered a risk factor (OR, 2.06; 95% CI, 0.93-4.55),
with the justiﬁcation that infrequent occurrences (n ¼ 29)
accounted for the borderline nonsigniﬁcance. The occurrence of
leakage was also few in our study (n ¼ 16), yet it could not be
deemed a risk factor owing to the wide, nonsigniﬁcant CI (OR, 1.6;
99% CI, 0.3-8.3). The same applies to tumor height. Few patients
had a tumor distance < 5 cm in our study (n ¼ 17), and despite
yielding the highest OR (OR, 3.6; 99% CI, 0.7-18.2), the CI was
very broad and nonsigniﬁcant. Although not directly comparable, it
is worth mentioning that tumor height was previously found in the
TME trial to be associated with fecal incontinence at 5 years, but
only in patients treated with PRT.23 The role of female gender,
anastomotic leakage, and tumor height in the occurrence of major
LARS requires additional clariﬁcation.
Only nonstoma patients were included in the present study.
However, it is known that some patients will subsequently receive a
colostomy, even after initial restoration of intestinal continuity,
because of severe bowel dysfunction. These patients would have
been excluded from the present study, and it is likely that the
patients in the PRTþTME group would have been more affected
by this effect, which might have reduced the difference in major
LARS rates observed between the 2 treatment groups.
The ﬁnding of younger patient age increasing the risk of
major LARS seems to be against the natural deterioration of
bowel function with age. Selection bias could have been at play,
with younger patients receiving more sphincter-preserving pro-
cedures. However, this was not the case in our study, because
the age at treatment between the patients undergoing low
anterior resection and abdominoperineal resection, as well as age
at follow-up between those with and without a stoma, were not
different (data not shown). One plausible explanation is that
elderly individuals have poorer bowel function at baseline and
hence would be less perceptive to changes after treatment.12 This
can be veriﬁed in future longitudinal studies by obtaining the
baseline LARS score.
Our study is not the ﬁrst to show an association between bowel
dysfunction, measured using the LARS score, and HRQL,
measured using the EORTC QLQ-C30. The study by Emmert-
sen et al11 demonstrated a close relationship between the 2,
focusing on the comparison of the EORTC QLQ-C30 scoresClinical Colorectal Cancer June 2015 - 111
Table 3 Comparison of EORTC QLQ-C30 and EORTC QLQ-CR29 Scores Between LARS Score Severity Categories
Domains/scales
Mean Score
P Value CSMajor LARS Minor or No LARS
EORTC QLQ-C30a
Global health status/QOLb,c 73.4 80.3 <.01 Yes
Physical functioningc 80.1 82.0 .35 No
Role functioningc 79.0 85.5 .03 Yes
Emotional functioningc 81.8 87.5 .02 Yes
Cognitive functioningb,c 80.9 87.7 <.01 Yes
Social functioningb,c 83.3 91.2 <.01 Yes
Fatigueb,d 27.0 18.6 <.01 Yes
Nausea and vomitingd 2.1 2.3 .99 No
Paind 14.5 9.7 .04 No
Dyspnead 15.0 13.6 .89 No
Insomniad 26.0 19.8 .05 Yes
Appetite lossd 5.6 6.9 .92 No
Constipationd 20.8 12.1 .02 Yes
Diarrheab,d 24.8 4.6 <.01 Yes
Financial difﬁcultiesd 6.1 3.6 .20 No
EORTC QLQ-CR29a
Body imageb,c 85.2 94.4 <.01 Yes
Anxietyb,c 77.0 85.9 <.01 Yes
Weightc 85.6 88.5 .26 No
Sexual interest (men)c 68.0 70.6 .81 No
Sexual interest (women)c 80.6 78.4 .82 No
Urinary frequencyd 33.3 25.3 .01 Yes
Blood and mucus in stoolb,d 5.7 0.6 <.01 Yes
Stool frequencyb,d 34.1 13.8 <.01 Yes
Urinary incontinenceb,d 17.1 10.1 <.01 Yes
Dysuriad 2.2 1.3 .51 No
Abdominal painb,d 13.3 3.4 <.01 Yes
Buttock painb,d 13.3 3.9 <.01 Yes
Bloatingb,d 19.1 7.6 <.01 Yes
Dry mouthd 26.0 17.2 .03 Yes
Hair lossd 3.2 2.8 .98 No
Tasted 4.8 2.8 .45 No
Flatulenceb,d 46.3 23.2 <.01 Yes
Fecal incontinenceb,d 27.5 7.6 <.01 Yes
Sore skinb,d 17.5 3.9 <.01 Yes
Embarrassmentb,d 36.6 11.1 <.01 Yes
Impotenced 66.7 62.2 .39 No
Dyspareuniad 22.2 6.1 .21 Yes
Abbreviations: CS ¼ clinically signiﬁcant; EORTC QLQ-C30 ¼ European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core; EORTC QLQ-CR29 ¼ European
Organization for Research and Treatment of Cancer Quality of Life Questionnaire Colorectal Module; LARS ¼ low anterior resection syndrome; QOL ¼ quality of life.
aScore range 0 to 100.
bDomains/scales that were both statistically and clinically signiﬁcant.
cHigher score indicates better health-related quality of life.
dHigher score indicates worse health-related quality of life.
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112 -between the major LARS and no LARS groups. In another study
by Juul et al,24 the EORTC QLQ-C30 scores were signiﬁcantly
(both statistically and clinically) different between the major
LARS and no LARS groups, and between the major LARS and
minor LARS groups, but not between the no LARS and minorClinical Colorectal Cancer June 2015LARS groups. The ﬁndings by Juul et al24 support our rationale of
comparing the EORTC QLQ-C30 scores for patients with major
LARS versus no or minor LARS.24 The conjoint application of the
more disease-speciﬁc EORTC QLQ-CR29 adds rigor to our
assessment.
Tina Yen-Ting Chen et alThe TME trial has established that PRT decreases local recur-
rence by more than one half (10-year cumulative incidence, 5% vs.
11%).5 The present very long-term follow-up study has demon-
strated that such beneﬁt is achieved at the expense of a threefold
increase in the odds of severe bowel dysfunction that persists even
> 14 years after treatment. Local recurrence causes disabling
symptoms, is challenging to treat, and treatment is associated with
substantial morbidity. It would be hard to argue that LARS is more
detrimental than local recurrence or that PRT should not be
offered to those at higher risk of LARS. The deﬁnitive prevention
and treatment of LARS is colostomy. Although the common
impression is that HRQL will be superior with sphincter preser-
vation than with colostomy after rectal cancer resection, a Cochrane
review could not draw ﬁrm conclusions about this,25 and the
compromised HRQL in patients with major LARS could have been
the reason. It has been revealed that the presence of a stoma and
fecal incontinence can be similarly troublesome for patients.26
However, a large number of nonstoma patients with fecal incon-
tinence still prefer this to life with a stoma.27 Therefore, patient
communication is key. Our study ﬁndings can be used to better
inform patients of the possible long-term consequences of PRT.
Ultimately, treatment decisions must be based on both patient
preference and clinical judgment, after a thorough deliberation of
treatment beneﬁts and risks of adverse effects. Bowel function
should be routinely and systematically assessed at the follow-up
visits, and patients should be educated about LARS. Several
options for managing LARS are available before resorting to
colostomy, including transanal irrigation and sacral neuro-
modulation, which are showing promising results. However, more
research is required to consolidate their effectiveness. Finally,
additional research is needed to corroborate whether enhanced ra-
diation and surgical techniques can lead to less long-term bowel
dysfunction.Conclusion
The present study has illustrated long-term survivorship issues in
rectal cancer. At 14.6 years, almost one half (46%) of the Dutch
TME trial patients without a stoma experienced major LARS.
Although a greater proportion of irradiated patients experienced
major LARS (56% vs. 35%), the ﬁnding that one third of the
nonirradiated patients had major LARS indicates that TME surgery
was most probably the main contributing factor, with PRT and
age  75 years at the follow-up point posing additional risks. Major
LARS was associated with poorer HRQL.
Clinical Practice Points
 TME is the reference standard surgical technique in treating
rectal cancer. The additional beneﬁt of PRT in decreasing local
recurrence combined with TME has been demonstrated in the
TME trial.
 In assessing the bowel function of the Dutch TME trial cohort >
14 years after treatment, we found that 46% of all patients (56%
PRTþTME vs. 35% TME) experienced major LARS, which
was associated with reduced HRQL.
 TME is probably the main contributing factor to major LARS,
with PRT and age  75 years at follow-up posing further risks. The additional beneﬁt of PRT in reducing local recurrence is
achieved at the expense of a threefold increase in the odds of
major LARS.
 The relative beneﬁts and risks of long-lasting adverse effects of
TME and PRT should be fully disclosed to patients to reach a
mutual treatment decision, especially given the emphasis on
sphincter preservation and improved survival.
 Bowel function should be routinely and systematically assessed at
the follow-up examinations, and patients should be educated about
LARS, including strategies to lessen the impact of symptoms.Acknowledgments
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